EGFR S768I

Loading variant…

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Adenocarcinoma4
EGFR S768I	Erlotinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID1394 A patient with metastatic lung adenocarcinoma was found to harbor EGFR T790M and S768I mutations when acquired resistance developed after 8 years of erlotinib treatment. Analysis of original tumor sam… (full text at CIViC) PMID 25521405 · Hellmann et al., 2014 · Open in CIViC	civic
EGFR S768I	Erlotinib	Predictive	C	Supports Resistance	—	accepted	EID4273 In stage IV lung adenocarcinoma patients (n=2) harboring EGFR S768I mutation, EGFR S768I was associated with progressive disease after 1 month of erlotinib monotherapy; the patient was previously trea… (full text at CIViC) PMID 22895145 · Lund-Iversen et al., 2012 · Open in CIViC	civic

Molecular profile

Therapy

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

Lung Adenocarcinoma4

EGFR S768I

Erlotinib

Predictive

Supports Sensitivity Response

accepted

EID1394

A patient with metastatic lung adenocarcinoma was found to harbor EGFR T790M and S768I mutations when acquired resistance developed after 8 years of erlotinib treatment. Analysis of original tumor sam… (full text at CIViC)

PMID 25521405 · Hellmann et al., 2014 · Open in CIViC

civic

EGFR S768I

Erlotinib

Predictive

Supports Resistance

—

accepted

EID4273

In stage IV lung adenocarcinoma patients (n=2) harboring EGFR S768I mutation, EGFR S768I was associated with progressive disease after 1 month of erlotinib monotherapy; the patient was previously trea… (full text at CIViC)

PMID 22895145 · Lund-Iversen et al., 2012 · Open in CIViC

civic

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
45251	Pathogenic	criteria provided, single submitter	1	Non-small cell lung carcinoma; Neoplasm	germline/somatic	3	Mar 11, 2011	clinvar

Variation

Clinical significance

Review status

Stars

Conditions

Origin

Submitters

Last evaluated

Source

45251

Pathogenic

criteria provided, single submitter

Non-small cell lung carcinoma; Neoplasm

germline/somatic

Mar 11, 2011

clinvar

Lung Non-Small Cell Carcinoma6
EGFR S768I	Erlotinib	Predictive	C	Does Not Support Sensitivity Response	2	accepted	EID2906 S768I mutations in exon 20 of the EGFR gene are rare and are typically seen in conjunction with sensitizing EGFR mutations. Because of this mutation's rarity and the variability of responses of treate… (full text at CIViC) PMID 27211795 · Leventakos et al., 2016 · Open in CIViC	civic
EGFR S768I	Erlotinib	Predictive	D	Supports Sensitivity Response	—	submitted	EID4185 In an in vitro study, a NIH3T3 cell line expressing EGFR R108K demonstrated increased sensitivity to erlotinib treatment comparable to NIH3T3 cells expressing EGFR L858R (a known sensitizing mutation … (full text at CIViC) PMID 17877814 · de Gunst et al., 2007 · Open in CIViC	civic
EGFR S768I	Gefitinib	Predictive	B	Supports Sensitivity Response	—	submitted	EID2614 In response to gefitinib treatment, lung adenocarcinoma patients with somatic EGFR S768I mutation had longer median progression-free survival when there was a concomitant L858R mutation or in-frame de… (full text at CIViC) PMID 19060236 · Wu et al., 2008 · Open in CIViC	civic
EGFR S768I	Gefitinib	Predictive	B	Supports Sensitivity Response	—	submitted	EID2615 Partial response to gefitinib was achieved in two non-small cell lung cancer patients having a S768I mutation with concomitant G719C mutation. PMID 15998907 · Takano et al., 2005 · Open in CIViC	civic
EGFR S768I	Gefitinib	Predictive	D	Supports Sensitivity Response	—	submitted	EID2616 In vitro studies showed that cells with S768I mutation had moderate sensitivity (IC50=90-315nM) to gefitinib , in comparison to the del747-753insS (IC50= 7nM) or L858R (IC50=12-20nM) mutations that co… (full text at CIViC) PMID 16205628 · Chen et al., 2006 · Open in CIViC	civic
EGFR S768I	Osimertinib	Predictive	B	Supports Sensitivity Response	4	submitted	EID7859 In a multicenter phase II trial in Korea, patients with NSCLC harboring EGFR mutations other than the exon 19 deletion, L858R, T790M, and exon 20 insertion were treated with osimertinib. Patients who … (full text at CIViC) PMID 31825714 · Cho et al., 2020 · Open in CIViC	civic

Lung Non-Small Cell Carcinoma6

EGFR S768I

Erlotinib

Predictive

Does Not Support Sensitivity Response

accepted

EID2906

S768I mutations in exon 20 of the EGFR gene are rare and are typically seen in conjunction with sensitizing EGFR mutations. Because of this mutation's rarity and the variability of responses of treate… (full text at CIViC)

PMID 27211795 · Leventakos et al., 2016 · Open in CIViC

civic

EGFR S768I

Erlotinib

Predictive

Supports Sensitivity Response

—

submitted

EID4185

In an in vitro study, a NIH3T3 cell line expressing EGFR R108K demonstrated increased sensitivity to erlotinib treatment comparable to NIH3T3 cells expressing EGFR L858R (a known sensitizing mutation … (full text at CIViC)

PMID 17877814 · de Gunst et al., 2007 · Open in CIViC

civic

EGFR S768I

Gefitinib

Predictive

Supports Sensitivity Response

—

submitted

EID2614

In response to gefitinib treatment, lung adenocarcinoma patients with somatic EGFR S768I mutation had longer median progression-free survival when there was a concomitant L858R mutation or in-frame de… (full text at CIViC)

PMID 19060236 · Wu et al., 2008 · Open in CIViC

civic

EGFR S768I

Gefitinib

Predictive

Supports Sensitivity Response

—

submitted

EID2615

Partial response to gefitinib was achieved in two non-small cell lung cancer patients having a S768I mutation with concomitant G719C mutation.

PMID 15998907 · Takano et al., 2005 · Open in CIViC

civic

EGFR S768I

Gefitinib

Predictive

Supports Sensitivity Response

—

submitted

EID2616

In vitro studies showed that cells with S768I mutation had moderate sensitivity (IC50=90-315nM) to gefitinib , in comparison to the del747-753insS (IC50= 7nM) or L858R (IC50=12-20nM) mutations that co… (full text at CIViC)

PMID 16205628 · Chen et al., 2006 · Open in CIViC

civic

EGFR S768I

Osimertinib

Predictive

Supports Sensitivity Response

submitted

EID7859

In a multicenter phase II trial in Korea, patients with NSCLC harboring EGFR mutations other than the exon 19 deletion, L858R, T790M, and exon 20 insertion were treated with osimertinib. Patients who … (full text at CIViC)

PMID 31825714 · Cho et al., 2020 · Open in CIViC

civic

Malignant Neoplasm1
EGFR S768I	Erlotinib + GefitinibSubstitutes	Predictive	D	Does Not Support Sensitivity Response	3	accepted	EID4274 In an in vitro study, a Ba/F3 cell line expressing EGFR S768I demonstrated reduced sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sen… (full text at CIViC) PMID 19147750 · Kancha et al., 2009 · Open in CIViC	civic

Malignant Neoplasm1

EGFR S768I

Erlotinib + GefitinibSubstitutes

Predictive

Does Not Support Sensitivity Response

accepted

EID4274

In an in vitro study, a Ba/F3 cell line expressing EGFR S768I demonstrated reduced sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sen… (full text at CIViC)

PMID 19147750 · Kancha et al., 2009 · Open in CIViC

civic

Evidence by cancer (11 items)

Clinical significance (1)